Clinical trial of ticagrelor tablets in the treatment of complex coronary artery disease
10.13699/j.cnki.1001-6821.2017.23.003
- VernacularTitle:替格瑞洛片治疗复杂冠心病的临床研究
- Author:
Shuai ZHOU
1
;
Luo-Sha ZHAO
;
Ke-Jun HUANG
Author Information
1. 河南省胸科医院心血管九病区,郑州450000
- Keywords:
ticagrelor tablet;
complex coronary artery disease;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(23):2335-2338
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of ticagrelor tablets in the treatment of complex coronary artery disease.Methods One hundred and twenty-five patients with complex coronary artery disease were randomly divided into control group (n =63 cases) and treatment groups (n =62 cases).Control group received clopidogrel hydrogen 300 mg per time before operation and 75 mg per time after operation,qd,orally.Treatment group was given ticagrelor 180 mg per time before operative and 90 mg per time after operation,qd,orally.Two groups were treated for 1 year.The clinical efficacy,cardiac function and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 87.10％ (54 cases/62 cases) and 71.43％ (45 cases/63 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:creatinine kinase-MB were (16.37 ±2.01) and (59.73 ± 10.62) μg · L-1,myoglobin were (42.08 ± 11.86) and (123.28 ± 50.63) μg · L-1,troponin T were (0.01 ±0.01) and (0.06 ± 0.03) μg · L-1,brain natriuretic peptide were (44.44 ± 3.11) and (68.62 ± 10.37) ng · L-1,left ventricular ejection fraction were (57.22 ± 1.61) ％ and (25.36±5.38)％,the differences were statistically significant (all P ＜0.05).The adverse drug reactions in two groups were bleeding,difficulty breathing and arrhythmia.The incidences of adverse drug reactions in treatment and control groups were 24.19％ and 31.75％ without significant difference (P ＞ 0.05).Conclusion Ticagrelor tablets have a definitive clinical efficacy in the treatment of complex coronary artery disease,which can significantly improve the cardiac functions,without increasing the incidence of adverse drug reactions.
